- About
Rho - Working
with Rho - Clinical
research services - Federal
research - Resource
center - Career
center - News &
events - Contact
us




Improving outcomes for transplant recipients
The Clinical Trials in Organ Transplantation (CTOT) project is a cooperative research program sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), with co-funding from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). CTOT is an investigative consortium for conducting clinical and associated mechanistic studies that will lead to improved outcomes for transplant recipients. The purpose of these studies is to improve short and long-term graft and patient survival.
CTOT supports research to:
Visit the CTOT website for more information.
As the Statistical and Clinical Coordinating Center (SACCC) for the CTOT program, Rho’s responsibilities encompass a broad range of functions for the clinical trials and mechanistic studies, which include:
Project team members coordinate activities to support the design and conduct of a series of clinical, mechanistic, and biomarker studies. Rho statisticians provide leadership for the design and analysis of clinical trials and studies of underlying mechanisms. They also collaborate with clinicians during concept development, providing statistical and clinical trial expertise essential to creating the protocol. The administrative and infrastructure support tools established for this project include:
David Iklé (Ph.D., Senior Statistical Scientist) is the Principal Investigator (PI) for this coordinating center.
| Protocol | Title |
| CTOT-01 | Noninvasive Monitoring in Kidney Transplantation |
| CTOT-02/CCTPT-02 | B-Cell Depletion by Anti-CD20 in Renal Allograft Recipients who Develop de novo Anti HLA Alloantibodies |
| CTOT-03 | Correlation of Donor Proinflammatory mRNA Profiles with Early Outcomes of Thoracic and Abdominal Transplantation |
| CTOT-04 | Noninvasive Diagnosis of Renal Allograft Rejection by Urinary Cell mRNA Profiling |
| CTOT-05 | Observational Study of Alloimmunity in Cardiac Transplant Recipients |
| CTOT-07 | Signatures for the Prediction, Diagnosis and Prognostication of Liver Allograft Rejection and recurrent Hepatitis C Disease |
| CTOT-08 | Development of Genomic Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients – Transplant Proteogenomics |
| CTOT-09 | Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation |
| CTOT-10 | Optimization of Belatacept Usage As A Means of Avoiding CNI and steroids in Renal Transplantation |
| CTOT-11 | Optimization of Belatacept Usage As A Means of Avoiding CNI and steroids in Renal Transplantation |
| CTOT-12/ITN524ST | An Observational Study to Assess the Prevalence of the Tolerance Signature in Renal Transplant Recipients |
| CTOT-14 | Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients |
| Studies in Development | |
| CTOT-13 | A prospective, randomized, multi-center, two-parallel arm study evaluating the overall efficacy and safety of desensitization therapy on selected patients awaiting heart transplantation |
| CTOT-15 | Optimization on NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation |
| CTOT-16 | Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation |